Natural Products Insider is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Home>Business Resources>Business Operations>Labs/Testing

ChromaDex Announces Top Line Results of its Second Human Clinical Trial

<p>ChromaDex Corp. (NASDAQ:CDXC announced today that the initial results of its second human clinical study of NIAGEN<sup>&reg;</sup> nicotinamide riboside chloride (NR) have confirmed NR significantly and sustainably raises the co-enzyme nicotinamide adenine dinucleotide (NAD+) in 140 healthy human volunteers over 8-weeks.</p>
TAGS: Healthy Living Ingredients Business Resources
Hide comments

More information about text formats

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish
Related
CBD sport drug testing.jpg
CBD sport drug testing
Mar 11, 2019
02_13 clinical trials.jpg
Boosting consumer trust with quality clinical evidence
Feb 13, 2019
Banned substances in sport are not always clearly defined.jpg
Banned substances in sport are not always clearly defined
Jan 28, 2019
shutterstock_543381454.jpg
Banned substance testing programs provide extended value to the sports nutrition market
Jan 11, 2019